biopharmadive.com
Cure8 news brief
Lilly’s Omvoh approved by FDA for Crohn’s
Medications
Regulatory Update
Adult patients
Patients On Biologics
Clinicians
Researchers
Crohn's disease
Ulcerative colitis
Why This Matters
An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can access the drug without prior failures on other therapies.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis, patients considering or already on biologic therapy, gastroenterologists, and clinicians involved in IBD treatment and formulary decisions.
Study Snapshot
Story typeCompany update
Evidence typeRegulatory update
Source depthFull source text
What To Know
The FDA cleared Omvoh for Crohn’s disease based on Phase 3 results and ongoing extension data reported by Lilly showing sustained benefit for many patients. The approval broadens the labeled use beyond the earlier ulcerative colitis indication (2023). Lilly and the article highlight the drug’s commercial potential but also note current modest sales to date.
Practical points: Some large pharmacy benefit managers have listed Omvoh as a first‑line therapy, which could affect how easy it is for patients to start the drug without trying other biologics first.
As with any newly approved medication, clinicians and patients should consult prescribing information and discuss risks, benefits, and insurance coverage when considering treatment. This summary is based on the published BiopharmaDive article and Lilly’s public statements; it does not provide medical advice.
Keep In Mind
The article is a regulatory/business news piece summarizing Lilly’s announcement and market context. The reported clinical benefits are described from Lilly’s Phase 3 and extension data; independent full study reports and prescribing information should be consulted for detailed efficacy and safety data. Coverage and cost will vary by insurer and region.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationbiopharmadive.com
Indexed viaBing News
Source typeCompany update
PublishedJan 16, 2025, 8:21 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
J&J adds to IL-23 options in Crohn's after FDA approval
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.